PE20120881A1 - Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6 - Google Patents

Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6

Info

Publication number
PE20120881A1
PE20120881A1 PE2011001879A PE2011001879A PE20120881A1 PE 20120881 A1 PE20120881 A1 PE 20120881A1 PE 2011001879 A PE2011001879 A PE 2011001879A PE 2011001879 A PE2011001879 A PE 2011001879A PE 20120881 A1 PE20120881 A1 PE 20120881A1
Authority
PE
Peru
Prior art keywords
phenyl
methyl
bencensulfonamide
piperazine
serotonin
Prior art date
Application number
PE2011001879A
Other languages
English (en)
Inventor
Andreas Haupt
Frauke Pohlki
Karla Drescher
Karsten Wicke
Liliane Unger
Ana-Lucia Relo
Anton Bespalov
Barbara Vogg
Gisela Backfisch
Juergen DELZER
Min Zhang
Yanbin Lao
Original Assignee
AbbVie Deutschland GmbH and Co KG
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120881(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Deutschland GmbH and Co KG, Abbvie Inc filed Critical AbbVie Deutschland GmbH and Co KG
Publication of PE20120881A1 publication Critical patent/PE20120881A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE PIPERAZINA U HOMOPIPERAZINA DE FORMULAS (I) O (I'), DONDE X ES UN ENLACE O N-R4; R1 ES H O METILO; R2 ES H O METILO; R3 ES H, ALQUILO C1-C3, FLUOR, ENTRE OTROS; R4 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C4, ENTRE OTROS; R5 ES H, F, Cl, ALQUILO C1-C2, ENTRE OTROS; R6 ES H, F O Cl; n ES 1 O 2. SON SOMPUESTOS PREFERIDOS: CLORHIDRATO DE N-(3-DIFLUOROMETOXI-FENIL)-4-METIL-3-PIPERAZIN-1-IL-BENCENSULFONAMIDA, CLORHIDRATO DE 1-[5-(3-DIFLUOROMETOXI-BENCENSULFONIL)-2-METIL-FENIL]-PIPERAZINA, CLORHIDRATO DE N-(4-DIFLUOROMETOXI-FENIL)-4-METIL-3-PIPERAZIN-1-IL-BENCENSULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS ACTUAN MODULANDO LOS RECEPTORES DE SEROTONINA 5-HT6 Y SON UTILES EN EL TRATAMIENTO DE DISFUNCIONES COGNITIVAS TALES COMO ENFERMEDAD DE ALZHEIMER, TRANSTORNOS DE LA PERSONALIDAD TALES COMO ESQUIZOFRENIA, TRANSTORNOS DE ALIMENTACION TALES COMO ANOREXIA, BULIMIA, ENTRE OTRAS
PE2011001879A 2009-04-30 2010-04-29 Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6 PE20120881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17405409P 2009-04-30 2009-04-30

Publications (1)

Publication Number Publication Date
PE20120881A1 true PE20120881A1 (es) 2012-08-24

Family

ID=42236832

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001879A PE20120881A1 (es) 2009-04-30 2010-04-29 Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6

Country Status (27)

Country Link
US (1) US8076326B2 (es)
EP (1) EP2432769B1 (es)
JP (1) JP5718898B2 (es)
KR (1) KR20120016639A (es)
CN (1) CN102459197B (es)
AR (1) AR076507A1 (es)
AU (1) AU2010243585B2 (es)
BR (1) BRPI1011875A2 (es)
CA (1) CA2759482A1 (es)
CL (1) CL2011002653A1 (es)
CO (1) CO6450637A2 (es)
CR (1) CR20110604A (es)
DO (1) DOP2011000326A (es)
EC (1) ECSP11011468A (es)
ES (1) ES2536779T3 (es)
HK (1) HK1163104A1 (es)
IL (1) IL215642A (es)
MX (1) MX2011011520A (es)
NZ (1) NZ595698A (es)
PE (1) PE20120881A1 (es)
RU (1) RU2535200C2 (es)
SG (1) SG175187A1 (es)
TW (1) TWI465438B (es)
UA (1) UA107080C2 (es)
UY (1) UY32604A (es)
WO (1) WO2010125134A1 (es)
ZA (1) ZA201107569B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
US8536169B2 (en) 2008-06-05 2013-09-17 Glaxo Group Limited Compounds
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
US8343959B2 (en) * 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
SI2899191T1 (sl) 2009-04-30 2017-11-30 Glaxo Group Limited Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012059432A1 (en) * 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
US20140120036A1 (en) * 2012-01-06 2014-05-01 Abbvie Inc. Radiolabeled 5-ht6 ligands
KR20150092764A (ko) * 2012-12-10 2015-08-13 에프. 호프만-라 로슈 아게 RORc 조절인자로서의 벤질 설폰아마이드 유도체
KR20150128863A (ko) * 2013-03-15 2015-11-18 에프. 호프만-라 로슈 아게 RORc 조절제로서 아릴 설파미드 및 설파메이트 유도체
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3134392B1 (en) 2014-04-19 2019-01-02 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
ATE296811T1 (de) * 1997-07-11 2005-06-15 Smithkline Beecham Plc Sulfonamid-derivate als 5-ht6 receptor antagonisten und verfahren zu ihrer herstellung
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818914D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002739D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
EA009647B1 (ru) 2001-05-11 2008-02-28 Биовитрум Аб Арилсульфонамидные соединения и их применение для лечения ожирения и диабета типа ii
AU2002309435B2 (en) * 2001-06-11 2008-08-14 Biovitrum Ab (Publ) Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes
ATE417838T1 (de) 2001-08-10 2009-01-15 Hoffmann La Roche Arylsulfonyl-derivate mit 5-ht 6-rezeptor- affinität
EP1476428B1 (en) * 2002-02-22 2010-11-17 Pharmacia & Upjohn Company LLC Pyridyl sulfone derivatives as 5-ht6 receptor ligands
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
US7381728B2 (en) 2004-07-28 2008-06-03 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
GB0419192D0 (en) * 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
JP2009533325A (ja) * 2006-03-17 2009-09-17 アストラゼネカ・アクチエボラーグ ５−ｈｔ６調節剤としての新規なテトラリン
KR20080112394A (ko) * 2006-04-19 2008-12-24 애보트 게엠베하 운트 콤파니 카게 세로토닌 5ｈｔ6 수용체의 조절에 반응하는 장애를 치료하기 위해 적합한 헤테로사이클릭 아릴설폰
WO2008087123A2 (en) 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction

Also Published As

Publication number Publication date
JP2012525354A (ja) 2012-10-22
ZA201107569B (en) 2013-04-24
AU2010243585B2 (en) 2014-08-07
RU2535200C2 (ru) 2014-12-10
IL215642A0 (en) 2012-01-31
AR076507A1 (es) 2011-06-15
MX2011011520A (es) 2012-06-19
DOP2011000326A (es) 2011-11-15
UY32604A (es) 2010-12-31
UA107080C2 (uk) 2014-11-25
NZ595698A (en) 2014-01-31
ECSP11011468A (es) 2011-12-30
TW201043606A (en) 2010-12-16
WO2010125134A1 (en) 2010-11-04
IL215642A (en) 2015-09-24
US8076326B2 (en) 2011-12-13
CO6450637A2 (es) 2012-05-31
CN102459197A (zh) 2012-05-16
AU2010243585A1 (en) 2011-11-17
US20100280014A1 (en) 2010-11-04
CL2011002653A1 (es) 2012-06-15
ES2536779T3 (es) 2015-05-28
EP2432769B1 (en) 2015-04-01
CA2759482A1 (en) 2010-11-04
HK1163104A1 (zh) 2012-09-07
SG175187A1 (en) 2011-11-28
TWI465438B (zh) 2014-12-21
RU2011148583A (ru) 2013-06-10
KR20120016639A (ko) 2012-02-24
CR20110604A (es) 2012-05-28
CN102459197B (zh) 2015-08-19
EP2432769A1 (en) 2012-03-28
JP5718898B2 (ja) 2015-05-13
BRPI1011875A2 (pt) 2018-06-19

Similar Documents

Publication Publication Date Title
PE20120881A1 (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20190913A1 (es) Derivados aromaticos de sulfonamida
PE20090057A1 (es) Compuestos y composiciones como moduladores de la actividad gpr119
PE20040960A1 (es) Derivados de piperazina acilados como agonistas del receptor de melanocortina-4
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20060487A1 (es) Derivados de 2-carbamida-4-feniltiazol como moduladores de la actividad de quimioquinas
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
AR072753A1 (es) Derivados de oxazina como inhibidores de 11 beta - hidroxiesteroiode deshidrogenasa 1
PE20070528A1 (es) Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
CL2007000396A1 (es) Compuestos derivados de benzoil-piperidina, moduladores del receptor 5ht2/d3; composicion farmaceutica que los comprende;y su uso en el tratamiento y/o prevencion de patologias delsnc, tales como psicosis, esquizofrenia, depresion, ansiedad,adiccion a drogas y problemas cognitivos.
PE20110703A1 (es) Acidos naftilaceticos
PE20061088A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
ATE525351T1 (de) Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20080889A1 (es) Aminometil-4-imidazoles
PE20061348A1 (es) DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa
PE20071023A1 (es) Azaciclilaminas-n-sustituidas como antagonistas de histamina-3
PE20080371A1 (es) N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed